Genesis Therapeutics GEMS AI collaboration

Incyte's first-quarter 2025 update says that in February 2025 the company and Genesis Therapeutics entered a strategic collaboration on the research, discovery and development of novel small-molecule medicines, initially for targets selected by Incyte. The same update says Incyte receives exclusive rights to develop and commercialize collaboration products leveraged through Genesis's GEMS artificial intelligence platform.